Differential Gene Expression in HIV-Infected Individuals Following ART - GSE44228
A paired analysis of peripheral blood mononuclear cells (PBMCs) isolated before and after antiretroviral therapy (ART) from a robust number of HIV-infected patients (N=36).
Results identify a total of 4,157 DEGs following ART in HIV-infected participants and the transition from a period of active virus replication before ART to one of viral suppression
--
This study evaluated PBMC gene expression in cells from 36 (4 dropped from analysis) recently HIV-infected individuals to identify differentially expressed genes following 48 weeks of ART
--
--
--
--
Sample ID | Age | Ethnicity | !Sample_title | batch | sdf file |
---|---|---|---|---|---|
GSM1080991 | 31 years | White | Pt1_before_drug | 1 | 4307579061.sdf |
GSM1080992 | 36 years | White | Pt2_before_drug | 1 | 4307579072.sdf |
GSM1080993 | 39 years | American Indian | Pt3_before_drug | 1 | 4307579061.sdf |
GSM1080994 | 38 years | White | Pt4_before_drug | 1 | 4307579061.sdf |
GSM1080995 | 52 years | White | Pt5_before_drug | 1 | 4307579061.sdf |
File |
---|
All fields are editable except the "Sample ID" column. To edit a cell, click within the cell. To edit a "date" cell, click on the calendar icon. To cancel an edit, press the ESC key.
Sample ID | Age | Ethnicity | !Sample Title | Batch | Sdf file | Treatment | Subject | Drug regimen | Reanalysis | Analysis | Cd4+ t cell count, cells/ul | Cd4+ t cell count measurement | Sex |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSM1080991 | 31 years |
White |
Pt1_before_drug |
1 |
4307579061.sdf |
baseline |
Pt1 |
NNRTI |
re-analysis of GSM477695 |
Patient included in analysis |
463.00 |
baseline |
Male |
GSM1080992 | 36 years |
White |
Pt2_before_drug |
1 |
4307579072.sdf |
baseline |
Pt2 |
NNRTI |
re-analysis of GSM477696 |
Patient included in analysis |
449.00 |
baseline |
Male |
GSM1080993 | 39 years |
American Indian |
Pt3_before_drug |
1 |
4307579061.sdf |
baseline |
Pt3 |
NNRTI |
re-analysis of GSM477697 |
Patient included in analysis |
226.00 |
baseline |
Male |
GSM1080994 | 38 years |
White |
Pt4_before_drug |
1 |
4307579061.sdf |
baseline |
Pt4 |
NNRTI |
re-analysis of GSM477698 |
Patient included in analysis |
310.50 |
baseline |
Male |
GSM1080995 | 52 years |
White |
Pt5_before_drug |
1 |
4307579061.sdf |
baseline |
Pt5 |
NNRTI |
re-analysis of GSM477699 |
Patient included in analysis |
388.00 |
baseline |
Male |
GSM1080996 | 42 years |
White |
Pt6_before_drug |
1 |
4307579072.sdf |
baseline |
Pt6 |
NNRTI |
re-analysis of GSM477700 |
Patient included in analysis |
413.67 |
baseline |
Male |
GSM1080997 | 24 years |
African American |
Pt7_before_drug |
1 |
4307579072.sdf |
baseline |
Pt7 |
NNRTI |
re-analysis of GSM477701 |
Patient included in analysis |
232.00 |
baseline |
Male |
GSM1080998 | 38 years |
White |
Pt8_before_drug |
1 |
4307579062.sdf |
baseline |
Pt8 |
NNRTI |
re-analysis of GSM477702 |
Patient included in analysis |
285.00 |
baseline |
Male |
GSM1080999 | 28 years |
White |
Pt9_before_drug |
1 |
4307579061.sdf |
baseline |
Pt9 |
NNRTI |
re-analysis of GSM477703 |
Patient included in analysis |
413.50 |
baseline |
Male |
GSM1081000 | 33 years |
Asian |
Pt10_before_drug |
1 |
4307579060.sdf |
baseline |
Pt10 |
NNRTI |
re-analysis of GSM477704 |
Patient included in analysis |
282.67 |
baseline |
Male |
GSM1081001 | 28 years |
White |
Pt11_before_drug |
1 |
4307579060.sdf |
baseline |
Pt11 |
NNRTI |
re-analysis of GSM477705 |
Patient included in analysis |
383.00 |
baseline |
Male |
GSM1081002 | 19 years |
White |
Pt12_before_drug |
1 |
4307579060.sdf |
baseline |
Pt12 |
NNRTI |
re-analysis of GSM477706 |
Patient included in analysis |
226.00 |
baseline |
Male |
GSM1081003 | 29 years |
White |
Pt13_before_drug |
2 |
4463361135.sdf |
baseline |
Pt13 |
PI |
re-analysis of GSM477707 |
Patient dropped from analysis |
404.57 |
baseline |
Male |
GSM1081004 | 50 years |
White |
Pt14_before_drug |
2 |
4463361135.sdf |
baseline |
Pt14 |
PI |
re-analysis of GSM477708 |
Patient dropped from analysis |
425.33 |
baseline |
Male |
GSM1081005 | 58 years |
White |
Pt15_before_drug |
2 |
4463361239.sdf |
baseline |
Pt15 |
PI |
re-analysis of GSM477709 |
Patient dropped from analysis |
454.33 |
baseline |
Male |
GSM1081006 | 50 years |
White |
Pt16_before_drug |
2 |
4463361135.sdf |
baseline |
Pt16 |
PI |
re-analysis of GSM477710 |
Patient dropped from analysis |
414.33 |
baseline |
Male |
GSM1081007 | 33 years |
White |
Pt17_before_drug |
2 |
4463361177.sdf |
baseline |
Pt17 |
PI |
re-analysis of GSM477711 |
Patient included in analysis |
221.50 |
baseline |
Male |
GSM1081008 | 24 years |
American Indian |
Pt18_before_drug |
2 |
4463361239.sdf |
baseline |
Pt18 |
PI |
re-analysis of GSM477712 |
Patient included in analysis |
362.00 |
baseline |
Male |
GSM1081009 | 39 years |
White |
Pt19_before_drug |
2 |
4463361156.sdf |
baseline |
Pt19 |
PI |
re-analysis of GSM477713 |
Patient included in analysis |
200.67 |
baseline |
Male |
GSM1081010 | 34 years |
African American |
Pt20_before_drug |
2 |
4463361239.sdf |
baseline |
Pt20 |
PI |
re-analysis of GSM477714 |
Patient included in analysis |
315.75 |
baseline |
Male |
GSM1081011 | 40 years |
Asian |
Pt21_before_drug |
2 |
4463361177.sdf |
baseline |
Pt21 |
PI |
re-analysis of GSM477715 |
Patient included in analysis |
224.00 |
baseline |
Male |
GSM1081012 | 37 years |
Asian |
Pt22_before_drug |
2 |
4463361156.sdf |
baseline |
Pt22 |
PI |
re-analysis of GSM477716 |
Patient included in analysis |
210.00 |
baseline |
Male |
GSM1081013 | 54 years |
White |
Pt23_before_drug |
2 |
4463361177.sdf |
baseline |
Pt23 |
PI |
re-analysis of GSM477717 |
Patient included in analysis |
272.50 |
baseline |
Male |
GSM1081014 | 27 years |
White |
Pt24_before_drug |
2 |
4463361177.sdf |
baseline |
Pt24 |
PI |
re-analysis of GSM477718 |
Patient included in analysis |
398.00 |
baseline |
Male |
GSM1081015 | 34 years |
White |
Pt25_before_drug |
2 |
4531933134.sdf |
baseline |
Pt25 |
Switchers |
New analysis |
Patient included in analysis |
401.50 |
baseline |
Male |
GSM1081016 | 43 years |
White |
Pt26_before_drug |
2 |
4531933134.sdf |
baseline |
Pt26 |
Switchers |
New analysis |
Patient included in analysis |
233.00 |
baseline |
Male |
GSM1081017 | 49 years |
White |
Pt27_before_drug |
2 |
4531933135.sdf |
baseline |
Pt27 |
Switchers |
New analysis |
Patient included in analysis |
368.00 |
baseline |
Male |
GSM1081018 | 36 years |
White |
Pt28_before_drug |
2 |
4531933139.sdf |
baseline |
Pt28 |
Switchers |
New analysis |
Patient included in analysis |
445.00 |
baseline |
Male |
GSM1081019 | 42 years |
Asian |
Pt29_before_drug |
2 |
4531933139.sdf |
baseline |
Pt29 |
Switchers |
New analysis |
Patient included in analysis |
578.00 |
baseline |
Male |
GSM1081020 | 45 years |
White |
Pt30_before_drug |
2 |
4531933137.sdf |
baseline |
Pt30 |
Switchers |
New analysis |
Patient included in analysis |
500.50 |
baseline |
Male |
GSM1081021 | 42 years |
White |
Pt31_before_drug |
2 |
4531933134.sdf |
baseline |
Pt31 |
Switchers |
New analysis |
Patient included in analysis |
491.50 |
baseline |
Male |
GSM1081022 | 47 years |
White |
Pt32_before_drug |
2 |
4531933139.sdf |
baseline |
Pt32 |
Switchers |
New analysis |
Patient included in analysis |
418.50 |
baseline |
Male |
GSM1081023 | 27 years |
White |
Pt33_before_drug |
2 |
4531933137.sdf |
baseline |
Pt33 |
Switchers |
New analysis |
Patient included in analysis |
305.00 |
baseline |
Male |
GSM1081024 | 29 years |
White |
Pt34_before_drug |
2 |
4531933134.sdf |
baseline |
Pt34 |
Switchers |
New analysis |
Patient included in analysis |
461.50 |
baseline |
Male |
GSM1081025 | 38 years |
White |
Pt35_before_drug |
2 |
4531933137.sdf |
baseline |
Pt35 |
Switchers |
New analysis |
Patient included in analysis |
233.50 |
baseline |
Male |
GSM1081026 | 34 years |
White |
Pt36_before_drug |
2 |
4531933135.sdf |
baseline |
Pt36 |
Switchers |
New analysis |
Patient included in analysis |
316.00 |
baseline |
Male |
GSM1081027 | 31 years |
White |
Pt1_after_drug |
1 |
4307579062.sdf |
antiretroviral therapy |
Pt1 |
NNRTI |
New analysis |
Patient included in analysis |
539.00 |
after 48 weeks |
Male |
GSM1081028 | 36 years |
White |
Pt2_after_drug |
1 |
4307579062.sdf |
antiretroviral therapy |
Pt2 |
NNRTI |
New analysis |
Patient included in analysis |
548.00 |
after 48 weeks |
Male |
GSM1081029 | 39 years |
American Indian |
Pt3_after_drug |
1 |
4307579072.sdf |
antiretroviral therapy |
Pt3 |
NNRTI |
New analysis |
Patient included in analysis |
471.00 |
after 48 weeks |
Male |
GSM1081030 | 38 years |
White |
Pt4_after_drug |
1 |
4307579062.sdf |
antiretroviral therapy |
Pt4 |
NNRTI |
New analysis |
Patient included in analysis |
663.00 |
after 48 weeks |
Male |
GSM1081031 | 52 years |
White |
Pt5_after_drug |
1 |
4307579060.sdf |
antiretroviral therapy |
Pt5 |
NNRTI |
New analysis |
Patient included in analysis |
320.00 |
after 48 weeks |
Male |
GSM1081032 | 42 years |
White |
Pt6_after_drug |
1 |
4307579072.sdf |
antiretroviral therapy |
Pt6 |
NNRTI |
New analysis |
Patient included in analysis |
504.00 |
after 48 weeks |
Male |
GSM1081033 | 24 years |
African American |
Pt7_after_drug |
1 |
4307579060.sdf |
antiretroviral therapy |
Pt7 |
NNRTI |
New analysis |
Patient included in analysis |
988.00 |
after 48 weeks |
Male |
GSM1081034 | 38 years |
White |
Pt8_after_drug |
1 |
4307579072.sdf |
antiretroviral therapy |
Pt8 |
NNRTI |
New analysis |
Patient included in analysis |
564.00 |
after 48 weeks |
Male |
GSM1081035 | 28 years |
White |
Pt9_after_drug |
1 |
4307579060.sdf |
antiretroviral therapy |
Pt9 |
NNRTI |
New analysis |
Patient included in analysis |
776.00 |
after 48 weeks |
Male |
GSM1081036 | 33 years |
Asian |
Pt10_after_drug |
1 |
4307579061.sdf |
antiretroviral therapy |
Pt10 |
NNRTI |
New analysis |
Patient included in analysis |
302.00 |
after 48 weeks |
Male |
GSM1081037 | 28 years |
White |
Pt11_after_drug |
1 |
4307579062.sdf |
antiretroviral therapy |
Pt11 |
NNRTI |
New analysis |
Patient included in analysis |
434.00 |
after 48 weeks |
Male |
GSM1081038 | 19 years |
White |
Pt12_after_drug |
1 |
4307579062.sdf |
antiretroviral therapy |
Pt12 |
NNRTI |
New analysis |
Patient included in analysis |
656.00 |
after 48 weeks |
Male |
GSM1081039 | 29 years |
White |
Pt13_after_drug |
2 |
4463361156.sdf |
antiretroviral therapy |
Pt13 |
PI |
New analysis |
Patient dropped from analysis |
492.00 |
after 48 weeks |
Male |
GSM1081040 | 50 years |
White |
Pt14_after_drug |
2 |
4463361156.sdf |
antiretroviral therapy |
Pt14 |
PI |
New analysis |
Patient dropped from analysis |
404.00 |
after 48 weeks |
Male |
GSM1081041 | 58 years |
White |
Pt15_after_drug |
2 |
4463361177.sdf |
antiretroviral therapy |
Pt15 |
PI |
New analysis |
Patient dropped from analysis |
544.00 |
after 48 weeks |
Male |
GSM1081042 | 50 years |
White |
Pt16_after_drug |
2 |
4463361156.sdf |
antiretroviral therapy |
Pt16 |
PI |
New analysis |
Patient dropped from analysis |
539.00 |
after 48 weeks |
Male |
GSM1081043 | 33 years |
White |
Pt17_after_drug |
2 |
4463361135.sdf |
antiretroviral therapy |
Pt17 |
PI |
New analysis |
Patient included in analysis |
791.00 |
after 48 weeks |
Male |
GSM1081044 | 24 years |
American Indian |
Pt18_after_drug |
2 |
4463361156.sdf |
antiretroviral therapy |
Pt18 |
PI |
New analysis |
Patient included in analysis |
476.00 |
after 48 weeks |
Male |
GSM1081045 | 39 years |
White |
Pt19_after_drug |
2 |
4463361239.sdf |
antiretroviral therapy |
Pt19 |
PI |
New analysis |
Patient included in analysis |
484.00 |
after 48 weeks |
Male |
GSM1081046 | 34 years |
African American |
Pt20_after_drug |
2 |
4463361177.sdf |
antiretroviral therapy |
Pt20 |
PI |
New analysis |
Patient included in analysis |
434.00 |
after 48 weeks |
Male |
GSM1081047 | 40 years |
Asian |
Pt21_after_drug |
2 |
4463361135.sdf |
antiretroviral therapy |
Pt21 |
PI |
New analysis |
Patient included in analysis |
678.00 |
after 48 weeks |
Male |
GSM1081048 | 37 years |
Asian |
Pt22_after_drug |
2 |
4463361239.sdf |
antiretroviral therapy |
Pt22 |
PI |
New analysis |
Patient included in analysis |
502.00 |
after 48 weeks |
Male |
GSM1081049 | 54 years |
White |
Pt23_after_drug |
2 |
4463361135.sdf |
antiretroviral therapy |
Pt23 |
PI |
New analysis |
Patient included in analysis |
806.00 |
after 48 weeks |
Male |
GSM1081050 | 27 years |
White |
Pt24_after_drug |
2 |
4463361239.sdf |
antiretroviral therapy |
Pt24 |
PI |
New analysis |
Patient included in analysis |
1078.00 |
after 48 weeks |
Male |
GSM1081051 | 34 years |
White |
Pt25_after_drug |
2 |
4531933135.sdf |
antiretroviral therapy |
Pt25 |
Switchers |
New analysis |
Patient included in analysis |
409.00 |
after 48 weeks |
Male |
GSM1081052 | 43 years |
White |
Pt26_after_drug |
2 |
4531933137.sdf |
antiretroviral therapy |
Pt26 |
Switchers |
New analysis |
Patient included in analysis |
257.00 |
after 48 weeks |
Male |
GSM1081053 | 49 years |
White |
Pt27_after_drug |
2 |
4531933134.sdf |
antiretroviral therapy |
Pt27 |
Switchers |
New analysis |
Patient included in analysis |
432.00 |
after 48 weeks |
Male |
GSM1081054 | 36 years |
White |
Pt28_after_drug |
2 |
4531933135.sdf |
antiretroviral therapy |
Pt28 |
Switchers |
New analysis |
Patient included in analysis |
577.00 |
after 48 weeks |
Male |
GSM1081055 | 42 years |
Asian |
Pt29_after_drug |
2 |
4531933137.sdf |
antiretroviral therapy |
Pt29 |
Switchers |
New analysis |
Patient included in analysis |
634.00 |
after 48 weeks |
Male |
GSM1081056 | 45 years |
White |
Pt30_after_drug |
2 |
4531933139.sdf |
antiretroviral therapy |
Pt30 |
Switchers |
New analysis |
Patient included in analysis |
680.00 |
after 48 weeks |
Male |
GSM1081057 | 42 years |
White |
Pt31_after_drug |
2 |
4531933139.sdf |
antiretroviral therapy |
Pt31 |
Switchers |
New analysis |
Patient included in analysis |
692.00 |
after 48 weeks |
Male |
GSM1081058 | 47 years |
White |
Pt32_after_drug |
2 |
4531933134.sdf |
antiretroviral therapy |
Pt32 |
Switchers |
New analysis |
Patient included in analysis |
639.00 |
after 48 weeks |
Male |
GSM1081059 | 27 years |
White |
Pt33_after_drug |
2 |
4531933139.sdf |
antiretroviral therapy |
Pt33 |
Switchers |
New analysis |
Patient included in analysis |
552.00 |
after 48 weeks |
Male |
GSM1081060 | 29 years |
White |
Pt34_after_drug |
2 |
4531933135.sdf |
antiretroviral therapy |
Pt34 |
Switchers |
New analysis |
Patient included in analysis |
710.00 |
after 48 weeks |
Male |
GSM1081061 | 38 years |
White |
Pt35_after_drug |
2 |
4531933135.sdf |
antiretroviral therapy |
Pt35 |
Switchers |
New analysis |
Patient included in analysis |
456.00 |
after 48 weeks |
Male |
GSM1081062 | 34 years |
White |
Pt36_after_drug |
2 |
4531933137.sdf |
antiretroviral therapy |
Pt36 |
Switchers |
New analysis |
Patient included in analysis |
676.00 |
after 48 weeks |
Male |
Name | ||
---|---|---|
All Samples | Default | View |
In order to make new Group Sets or change settings, please log in. |
Group Set | |
---|---|
All Samples |